Clinical Trial Update: Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ [Phase 1]

View source ↗

Summary

Phase 1 study evaluating substance P neurotransmission in panic disorder using PET imaging of NK1 receptors with the radiotracer [18F]SPA-RQ; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Panic Disorder

Drugs mentioned

• [18F]SPA-RQ (SPA-RQ radiotracer)

Snippet

Sponsor: National Institute of Mental Health (NIMH) | Conditions: Panic Disorder, Healthy | Phase 1 | Status: COMPLETED